- Home
- MIRA vs SABS Comparison
MIRA vs SABS Comparison
Compare MIRA & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- SABS
- Stock Information
- Founded
- MIRA 2020
- SABS 2014
- Country
- MIRA United States
- SABS United States
- Employees
- MIRA N/A
- SABS N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- SABS Health Care
- Exchange
- MIRA Nasdaq
- SABS Nasdaq
- Market Cap
- MIRA 33.7M
- SABS 31.2M
- IPO Year
- MIRA 2023
- SABS N/A
- Fundamental
- Price
- MIRA $1.49
- SABS $4.09
- Analyst Decision
- MIRA
- SABS Strong Buy
- Analyst Count
- MIRA 0
- SABS 3
- Target Price
- MIRA N/A
- SABS $9.00
- AVG Volume (30 Days)
- MIRA 286.8K
- SABS 203.1K
- Earning Date
- MIRA 11-13-2025
- SABS 11-13-2025
- Dividend Yield
- MIRA N/A
- SABS N/A
- EPS Growth
- MIRA N/A
- SABS N/A
- EPS
- MIRA N/A
- SABS N/A
- Revenue
- MIRA N/A
- SABS $114,698.00
- Revenue This Year
- MIRA N/A
- SABS N/A
- Revenue Next Year
- MIRA N/A
- SABS N/A
- P/E Ratio
- MIRA N/A
- SABS N/A
- Revenue Growth
- MIRA N/A
- SABS N/A
- 52 Week Low
- MIRA $0.73
- SABS $1.00
- 52 Week High
- MIRA $2.45
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- MIRA 52.64
- SABS 71.11
- Support Level
- MIRA $1.33
- SABS $3.68
- Resistance Level
- MIRA $1.45
- SABS $4.15
- Average True Range (ATR)
- MIRA 0.09
- SABS 0.31
- MACD
- MIRA -0.00
- SABS 0.04
- Stochastic Oscillator
- MIRA 79.63
- SABS 93.18
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.